Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Childhood Brain Tumors: Molecular Marker to Facilitate Prognosis and Treatment Planning

06.12.2005


Valuable results for the complex jigsaw puzzle of cancer development



CDK6 is the plain name of a molecule that is often characteristically altered in medulloblastoma. This type of cancer is among the most common malignant brain tumors in children. Heidelberg molecular geneticians of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now found out that CDK6 can serve as an important indicator to help physicians determine the prognosis of patients. The results obtained in a project of the National Genome Research Network within the Brain Tumor Network have been published in the latest issue of the Journal of Clinical Oncology.

The typical age at the onset of medulloblastoma is seven years. Frequently, the tumor has already spread to other parts of the body. Despite intensive treatment almost half of the young patients die of this cancer. To be able to evaluate the course of such a tumor disease based on characteristic molecular markers and to develop novel treatment strategies, cancer researchers are trying to elucidate the development of the disease.


Frank Mendrzyk and Dr. Bernhard Radlwimmer of the Molecular Genetics Division have now contributed an important puzzle piece. The two researchers used the matrix-CGH technology developed by their divisional head Professor Peter Lichter to identify genetic alterations in medulloblastoma. Working with tissue samples of brain tumors they started by searching the whole genome for overrepresented and underrepresented segments of genetic material. Then they used immunological detection methods to investigate how identified candidate genes of these regions and their products are interconnected with the stage and course of the disease. This study was based on tumor tissue obtained from more than 200 patients whose medical records are known. The investigators found out that an increased number of gene copies is associated with overproduction of CDK6 and an unfavorable course of the disease. The gene located on chromosome 7 appears to play a key role in signaling pathways influencing growth and differentiation of medulloblastoma cells and other tumor cells. Compared to previously available markers, CDK6 seems to be an independent and at the same time more reliable source of information. Moreover, the gene product is easy to detect with immunological methods that are already established in routine diagnostics. CDK6 is also useful in clinical trials when it comes to evaluating the response to a treatment strategy.

The molecular geneticians have even more valuable findings to present. A factor called PPM1D is typically overproduced in medulloblastoma due to amplification of DNA segments on chromosome 17. The gene is not unknown to scientists. It is also found in multiple copies in neuroblastoma as well as in breast and ovarian cancer. Earlier publications have presented evidence suggesting that these alterations of the genetic information play a role in cancer development. Thus, other scientists showed in mouse embryonic cells that PPM1D is capable of abrogating the function of tumor suppressor gene TP53. TP53, jointly with other genes, regulates cell multiplication and thus reduces the likelihood of a cell turning into a tumor cell. Conversely, cells were resistant to transformation when they lacked PPM1D.

Further analyses and functional studies need to be performed in order to understand the exact role these genes play in the development of medulloblastoma. Eventually, cancer researchers are hoping to use this knowledge to find new targets for therapies and thus positively influence the course of the disease.

The task of the Deutsches Krebsforschungszentrum in Heidelberg (German Cancer Research Center, DKFZ) is to systematically investigate the mechanisms of cancer development and to identify cancer risk factors. The results of this basic research are expected to lead to new approaches in the prevention, diagnosis and treatment of cancer. The Center is financed to 90 percent by the Federal Ministry of Education and Research and to 10 percent by the State of Baden-Wuerttemberg. It is a member of the Helmholtz Association of National Research Centers (Helmholtz-Gemeinschaft Deutscher Forschungszentren e.V., HGF).

Julia Rautenstrauch | alfa
Further information:
http://www.dkfz.de/en/genetics/index.html

More articles from Life Sciences:

nachricht How molecules teeter in a laser field
18.01.2019 | Forschungsverbund Berlin

nachricht Discovery of enhanced bone growth could lead to new treatments for osteoporosis
18.01.2019 | University of California - Los Angeles

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Ten-year anniversary of the Neumayer Station III

The scientific and political community alike stress the importance of German Antarctic research

Joint Press Release from the BMBF and AWI

The Antarctic is a frigid continent south of the Antarctic Circle, where researchers are the only inhabitants. Despite the hostile conditions, here the Alfred...

Im Focus: Ultra ultrasound to transform new tech

World first experiments on sensor that may revolutionise everything from medical devices to unmanned vehicles

The new sensor - capable of detecting vibrations of living cells - may revolutionise everything from medical devices to unmanned vehicles.

Im Focus: Flying Optical Cats for Quantum Communication

Dead and alive at the same time? Researchers at the Max Planck Institute of Quantum Optics have implemented Erwin Schrödinger’s paradoxical gedanken experiment employing an entangled atom-light state.

In 1935 Erwin Schrödinger formulated a thought experiment designed to capture the paradoxical nature of quantum physics. The crucial element of this gedanken...

Im Focus: Nanocellulose for novel implants: Ears from the 3D-printer

Cellulose obtained from wood has amazing material properties. Empa researchers are now equipping the biodegradable material with additional functionalities to produce implants for cartilage diseases using 3D printing.

It all starts with an ear. Empa researcher Michael Hausmann removes the object shaped like a human ear from the 3D printer and explains:

Im Focus: Elucidating the Atomic Mechanism of Superlubricity

The phenomenon of so-called superlubricity is known, but so far the explanation at the atomic level has been missing: for example, how does extremely low friction occur in bearings? Researchers from the Fraunhofer Institutes IWM and IWS jointly deciphered a universal mechanism of superlubricity for certain diamond-like carbon layers in combination with organic lubricants. Based on this knowledge, it is now possible to formulate design rules for supra lubricating layer-lubricant combinations. The results are presented in an article in Nature Communications, volume 10.

One of the most important prerequisites for sustainable and environmentally friendly mobility is minimizing friction. Research and industry have been dedicated...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Our digital society in 2040

16.01.2019 | Event News

11th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Aachen, 3-4 April 2019

14.01.2019 | Event News

ICTM Conference 2019: Digitization emerges as an engineering trend for turbomachinery construction

12.12.2018 | Event News

 
Latest News

Additive manufacturing reflects fundamental metallurgical principles to create materials

18.01.2019 | Materials Sciences

How molecules teeter in a laser field

18.01.2019 | Life Sciences

The cytoskeleton of neurons has been found to be involved in Alzheimer's disease

18.01.2019 | Health and Medicine

VideoLinks
Science & Research
Overview of more VideoLinks >>>